Cellceutix Reaches Agreement with Former CEO and Cancels Reverse Split

Short and Sweet Press Release Says A LOT -

Cellceutix Corporation (CTIX)

Cellceutix Corporation (CTIX) has been quiet for several months now, but the Company released very good news today.  An agreement has been reached with former CEO George Evans to address all outstanding issues, which is great to allow Cellceutix to continue to focus on the tasks at hand, but, even more importantly, the thought of a reverse split to handle the settlement has now been canceled.  Additionally, the shares that will be bought back from Mr. Evans will be retired.  That means that nearly 5 million shares will be removed from the overall outstanding share balance, which is only in the area of 90 million presently.  As clinical trials approach, Cellceutix has continued to maintain its share structure for the good of its shareholders and is even going to reduce that amount further.  The full press release:

Cellceutix Announces Settlement with Former CEO

BEVERLY, MA — (Marketwire) — 02/14/11 — Cellceutix Corporation (PINKSHEETS: CTIX) announced today that it has reached a settlement agreement on all outstanding claims and issues between the Company and George W. Evans, the Company’s former Chief Executive Officer.

The terms of the agreement provides that the Company shall purchase 4,602,312 common shares held by Mr. Evans and/or Mr. Evans’ sons over a period of three years for a total sum of one million dollars. All options granted to Mr. Evans will be cancelled. The purchased shares will then be retired by the Company.

The Board wishes to thank Mr. Evans for his leadership and contribution to the Company’s development over the past 3 years.

Rescission of authorization to reverse split of common stock

In a separate board action, the board unanimously voted to rescind the authorization to effect a reverse split of its common stock.


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix

Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix(0)

Ecosphere Technologies, Inc. (OTCBB: ESPH) said Monday that it delivered two more Ozonix EF80 units to Hydrozonix LLC as part of a long-term contract with water treatment solutions company. Hydrozonix is a strategic alliance of a consortium of the principals at Phillips and Jordan, Inc., the Siboney Group and PBA Holdings that provides mobile, eco-friendly

Glaxo Genital Herpes Vaccine Flops but Genocea a Buy in Vaccine Space

Glaxo Genital Herpes Vaccine Flops but Genocea a Buy in Vaccine Space(0)

By Rex Graham A Glaxo Smith Kline (GSK) genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc. (AGEN), Vical, Inc. (VICL), and Sanofi Pasteur (SNY) offer new hope for an effective vaccine treatment. A Yale University study published in the Nov. 15, 2012,

Senate Approves Tax Hikes and Delay in Spending Cuts

Senate Approves Tax Hikes and Delay in Spending Cuts(0)

Technically, the United States has gone over the fiscal cliff with January 1 arriving before a new budget was passed to avert a series of automatic tax increases and deep spending cuts. But, the Senate said Tuesday morning that the White House and Senate Republicans have come to terms to raise taxes on households bringing-in

ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer

ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer(0)

Health information company ALR Technologies, Inc. (OTCBB: ALRT) on Monday disclosed the appointment of William S. Smith as Chief Commercial Officer and member of the Board of Directors, effective January 1, 2013.  Smith will oversee sales and marketing, investor relations, public affairs, communications and government affairs, according to a corporate statement. Previously, Smith spent ten

Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump

Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump(0)

Cellceutix Enters Into a $10 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, today announced that it has entered into a common stock purchase agreement

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.